Skip to main content
NCBI home page
Bulletin of the World Health Organization logoLink to Bulletin of the World Health Organization
. 1990;68(4):493–504.

Ascertainment of risk of serious adverse reactions associated with chemoprophylactic antimalarial drugs.

P A Phillips-Howard 1, A B Bjorkman 1
PMCID: PMC2393152  PMID: 2208562

Abstract

Serious adverse reactions during malaria chemoprophylaxis are reviewed. Three drugs considered to have caused serious reactions in recent years are pyrimethamine/sulfadoxine (Fansidar), pyrimethamine/dapsone (Maloprim) and amodiaquine. These reactions are principally independent of dose and cannot be determined during screening for optimal doses. However, host factors may precipitate dose-dependent reactions, some of which could be avoided with improvements in drug licensing. Since serious and life-threatening reactions are relatively rare (between 1:1000 and 1:20,000), Phase I to III trials cannot identify them. Reliance must therefore be placed on Phase IV post-marketing studies, including ongoing reviews of national registers, and specially tailored studies to identify the risk using prescription-event monitoring in high-risk populations. Occasionally, medical-record linkage, case-control and cohort studies may provide supportive data. Although large numbers of travellers must, of necessity, be exposed to a drug before relatively rare reactions are identified, the ascertainment of risk using post-marketing surveillance was prevented by the following five deficiencies: lack of awareness of early alerts, inadequate use of national registers, poor attention to epidemiological and statistical rigour, inadequate verification of denominators, and inadequacy of data records. Recommendations are given for minimizing such errors in the future.

Full text

PDF
493

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adams S. J., Broadbent J., Clayden L. M., Ridley C. M. Erythema multiforme (Stevens-Johnson) precipitated by Fansidar. Postgrad Med J. 1985 Mar;61(713):263–264. doi: 10.1136/pgmj.61.713.263. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Booth F., Barker L. C., Barton C. J., Naik R. B. Agranulocytosis during malaria prophylaxis with Maloprim (pyrimethamine and dapsone). Postgrad Med J. 1984 Aug;60(706):566–567. doi: 10.1136/pgmj.60.706.566. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Browne S. G., Ridge E. Toxic Epidermal Necrolysis. Br Med J. 1961 Feb 25;1(5225):550–553. doi: 10.1136/bmj.1.5225.550. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Carr R. Neutropenia and prophylactic amodiaquine. Lancet. 1986 Mar 8;1(8480):556–556. doi: 10.1016/s0140-6736(86)90908-6. [DOI] [PubMed] [Google Scholar]
  5. Davidson A. C., Bateman C., Shovlin C., Marrinan M., Burton G. H., Cameron I. R. Pulmonary toxicity of malaria prophylaxis. BMJ. 1988 Nov 12;297(6658):1240–1241. doi: 10.1136/bmj.297.6658.1240. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Dutta R. K. Erythema multiforme bullosum due to dapsone. Lepr India. 1980 Apr;52(2):306–309. [PubMed] [Google Scholar]
  7. Fish D. R., Espir M. L. Convulsions associated with prophylactic antimalarial drugs: implications for people with epilepsy. BMJ. 1988 Aug 20;297(6647):526–527. doi: 10.1136/bmj.297.6647.526. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Frey H. M., Gershon A. A., Borkowsky W., Bullock W. E. Fatal reaction to dapsone during treatment of leprosy. Ann Intern Med. 1981 Jun;94(6):777–779. doi: 10.7326/0003-4819-94-6-777. [DOI] [PubMed] [Google Scholar]
  9. Gillespie P., Wagner F. Amodiaquine agranulocytosis. Med J Aust. 1977 Feb 26;1(9):298–299. doi: 10.5694/j.1326-5377.1977.tb130706.x. [DOI] [PubMed] [Google Scholar]
  10. Grayson M. L., Yung A. P., Doherty R. R. Severe dapsone syndrome due to weekly maloprim. Lancet. 1988 Mar 5;1(8584):531–531. doi: 10.1016/s0140-6736(88)91321-9. [DOI] [PubMed] [Google Scholar]
  11. Haramburu F., Begaud B., Pere J. C., Marcel S., Albin H. Role of medical journals in adverse drug reaction alerts. Lancet. 1985 Sep 7;2(8454):550–551. doi: 10.1016/s0140-6736(85)90480-5. [DOI] [PubMed] [Google Scholar]
  12. Hellgren U., Rombo L. Malaria prophylaxis and epilepsy. BMJ. 1988 Nov 12;297(6658):1267–1267. doi: 10.1136/bmj.297.6658.1267. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Hutchinson D. B., Whiteman P. D., Farquhar J. A. Agranulocytosis associated with maloprim: review of cases. Hum Toxicol. 1986 Jul;5(4):221–227. doi: 10.1177/096032718600500402. [DOI] [PubMed] [Google Scholar]
  14. Jeffrey R. F. Transient lupus anticoagulant and fansidar therapy. Postgrad Med J. 1986 Sep;62(731):893–894. doi: 10.1136/pgmj.62.731.893. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Lal S., Garg B. R. Sulphone induced exfoliative dermatitis and hepatitis. Lepr India. 1980 Apr;52(2):302–305. [PubMed] [Google Scholar]
  16. Langtry J. A., Harper J. I., Staughton R. C., Barrington P. Erythroderma resembling sézary syndrome after treatment with Fansidar and chloroquine. Br Med J (Clin Res Ed) 1986 Apr 26;292(6528):1107–1108. doi: 10.1136/bmj.292.6528.1107-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Lazar H. P., Murphy R. L., Phair J. P. Fansidar and hepatic granulomas. Ann Intern Med. 1985 May;102(5):722–722. doi: 10.7326/0003-4819-102-5-722_1. [DOI] [PubMed] [Google Scholar]
  18. MOESCHLIN S., WAGNER K. [Agranulocytosis due to the occurrence of leukocyte-agglutinins; pyramidon and cold agglutinins]. Acta Haematol. 1952 Jul-Aug;8(1-2):29–41. doi: 10.1159/000204146. [DOI] [PubMed] [Google Scholar]
  19. McCormack D., Morgan W. K. Fansidar hypersensitivity pneumonitis. Br J Dis Chest. 1987 Apr;81(2):194–196. doi: 10.1016/0007-0971(87)90140-9. [DOI] [PubMed] [Google Scholar]
  20. McKenna W. B., Chalmers A. C. Agranulocytosis Following Dapsone Therapy. Br Med J. 1958 Feb 8;1(5066):324–325. doi: 10.1136/bmj.1.5066.324. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Mohamed K. N. Hypersensitivity reaction to dapsone: report from Malaysia. Lepr Rev. 1984 Dec;55(4):385–389. doi: 10.5935/0305-7518.19840044. [DOI] [PubMed] [Google Scholar]
  22. Neftel K. A., Woodtly W., Schmid M., Frick P. G., Fehr J. Amodiaquine induced agranulocytosis and liver damage. Br Med J (Clin Res Ed) 1986 Mar 15;292(6522):721–723. doi: 10.1136/bmj.292.6522.721. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Ognibene A. J. Agranulocytosis due to dapsone. Ann Intern Med. 1970 Apr;72(4):521–524. doi: 10.7326/0003-4819-72-4-521. [DOI] [PubMed] [Google Scholar]
  24. Olsen V. V., Loft S., Christensen K. D. Serious reactions during malaria prophylaxis with pyrimethamine-sulfadoxine. Lancet. 1982 Oct 30;2(8305):994–994. doi: 10.1016/s0140-6736(82)90202-1. [DOI] [PubMed] [Google Scholar]
  26. Peto T. E., Gilks C. F. Strategies for the prevention of malaria in travellers: comparison of drug regimens by means of risk-benefit analysis. Lancet. 1986 May 31;1(8492):1256–1261. doi: 10.1016/s0140-6736(86)91395-4. [DOI] [PubMed] [Google Scholar]
  27. Phillips-Howard P. A., Warwick Buckler J. Idiosyncratic reaction resembling toxic epidermal necrolysis caused by chloroquine and maloprim. Br Med J (Clin Res Ed) 1988 Jun 4;296(6636):1605–1605. doi: 10.1136/bmj.296.6636.1605. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Phillips-Howard P. A., West L. J. Serious adverse drug reactions to pyrimethamine-sulphadoxine, pyrimethamine-dapsone and to amodiaquine in Britain. J R Soc Med. 1990 Feb;83(2):82–85. doi: 10.1177/014107689008300208. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Rhodes E. G., Ball J., Franklin I. M. Amodiaquine induced agranulocytosis: inhibition of colony growth in bone marrow by antimalarial agents. Br Med J (Clin Res Ed) 1986 Mar 15;292(6522):717–718. doi: 10.1136/bmj.292.6522.717. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Rombo L., Stenbeck J., Lobel H. O., Campbell C. C., Papaioanou M., Miller K. D. Does chloroquine contribute to the risk of serious adverse reactions to fansidar? Lancet. 1985 Dec 7;2(8467):1298–1299. doi: 10.1016/s0140-6736(85)91574-0. [DOI] [PubMed] [Google Scholar]
  31. Tomecki K. J., Catalano C. J. Dapsone hypersensitivity. The sulfone syndrome revisited. Arch Dermatol. 1981 Jan;117(1):38–39. doi: 10.1001/archderm.117.1.38. [DOI] [PubMed] [Google Scholar]

Articles from Bulletin of the World Health Organization are provided here courtesy of World Health Organization

RESOURCES